<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33559">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031419</url>
  </required_header>
  <id_info>
    <org_study_id>CC-122-DLBCL-001</org_study_id>
    <nct_id>NCT02031419</nct_id>
  </id_info>
  <brief_title>Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292 and Rituximab in Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Netherlands:  Independent Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First study, at multiple clinical centers, exploring the effects of different combinations
      of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma
      (DLBCL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122,
      CC-223 and CC-292 administered orally as doublets with or without rituximab, in subjects
      with relapsed/refractory DLBCL who have failed standard therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From the time of informed consent, throughout dosing period and for 28 days after the last dose of study drug.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine safety profiles and dose-limiting toxicities of study drug combinations using NCI CTCAE v4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Every 2-3 months until proof of tumor progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor response rates using Cheson Revised Response Criteria for Malignant Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CC-223 and CC-292 interaction</measure>
    <time_frame>Day 1, Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-122</intervention_name>
    <description>2mg or 3 mg administered orally once daily</description>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223</intervention_name>
    <description>20mg or 30mg administered orally once daily.</description>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 administered intravenously once every 28 days</description>
    <arm_group_label>CC-122 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-122</intervention_name>
    <description>2mg or 3mg administered orally once daily.</description>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-292</intervention_name>
    <description>500 mg twice a day administered orally.</description>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 administered intravenously once every 28 days</description>
    <arm_group_label>CC-122 + CC-292 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223</intervention_name>
    <description>20mg or 30mg per day administered orally daily.</description>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-292</intervention_name>
    <description>500 mg twice a day administered orally.</description>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 administered intravenously once every 28 days</description>
    <arm_group_label>CC-292 + CC-223 +/- rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven Diffuse large B-cell lymphoma (DLBCL) (including transformed low grade
             lymphoma)

          -  Relapsed or refractory to prior standard treatment regimens

          -  At least one site of measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

          -  Subjects must have the following laboratory values:

               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L (with bone marrow
                  involvement with DLBCL)

               -  Hemoglobin (Hgb) ≥ 8 g/dL.

               -  Platelets ≥ 50 x 109/L without transfusion for 7 days.

               -  Potassium within normal limits

               -  Asparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and
                  Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) ≤ 2.5 x
                  Upper Limit of Normal (ULN) or ≤ 5.0 X ULN if liver tumor is present.

               -  Serum bilirubin ≤ 1.5 x ULN.

               -  Estimated serum creatinine clearance of ≥ 50 mL/min

        Exclusion Criteria:

          -  Symptomatic central nervous system involvement.

          -  Known symptomatic acute or chronic pancreatitis.

          -  Persistent diarrhea or malabsorption despite medical management.

          -  Peripheral neuropathy ≥ grade 2

          -  Impaired cardiac function or clinically significant cardiac diseases

          -  Subjects with diabetes on active treatment (for subjects treated on CC-223 containing
             arms only)

          -  Prior autologous stem cell transplant (ASCT) ≤ 3 months before first dose.

          -  Prior allogeneic stem cell transplant with either standard or reduced intensity
             conditioning.

          -  Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half
             lives or 4 weeks prior to starting study drugs, whichever is shorter.

          -  Subjects who have undergone major surgery ≤ 2 weeks prior to starting study drugs.

          -  Women who are pregnant or breast feeding. Adults of reproductive potential not
             willing to employ two forms of birth control.

          -  Subjects with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV)
             infection.

          -  Subjects with treatment-related myelodysplastic syndrome.

          -  History of concurrent second cancers requiring active, ongoing systemic treatment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pourdehnad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lee Moffitt Cancer Center and Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret, Lymphoma Clinic, Blood &amp; Marrow Transplant Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>INT-Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas-Humanitas Cancer</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza-corso- Bramante</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-122</keyword>
  <keyword>CC-223</keyword>
  <keyword>CC-292</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
